As part of the ‘Evénement économique 2017’ that took place on November 9, the Geneva Chamber of Commerce, Industry and Services (CCIG), the Department of Security and Economy (DSE) and the Office for the Promotion of Industries and Technologies (OPI) awarded the Innovation Prize 2017 to the Drugs for Neglected Diseases initiative (DNDi).
GARDP has set up its team, scientific advisory committee, and R&D strategy. Three programmes are underway: neonatal sepsis, gonorrhoea, and an initiative to recover and connect the vital knowledge of scientists in antibiotic drug development. In recent weeks, both the G20 Health Ministers and outgoing WHO Director-General Margaret Chan have expressed support for GARDP and called for more R&D into drug-resistant infections.
Bernard Pécoul, Executive Director, DNDi
Ambitious targets serve the obvious purpose of galvanising the NTD community around a shared goal, and the London Declaration succeeded in bringing new actors to the table and casting a much-needed spotlight on the neglect of these diseases. But the job is far from done, and we should not be lulled into a sense of security or complacency by too much celebrating of good news.
Thirty-five year old Tsadik is a visceral leishmaniasis (VL) patient who is also infected with HIV. He is gaunt, weak and tired, with sunken eyes. Each breath he takes is laboured. Tsadik lives in Abdurafi, a region of northwest Ethiopia that is characterized with high VL-HIV co-infection because VL is endemic….
Sani sits in the doorway of her one-room house with her baby girl Mel in her arms. A pink sunset illuminates the Durban township of KwaMashu that unfolds below her clifftop house. She looks lovingly at Mel, then takes out a syringe and struggles to give the two-year-old,a medicine that is over 40% alcohol.
Graeme Bilbe, Research & Development Director, DNDi
‘We need to ensure that results of R&D are affordable and available to patients’
DNDi’s R&D Director Graeme Bilbe looks back on 2016 and the exciting advances in DNDi’s portfolio, and explains what he sees as the biggest challenges facing the organization.
The implementation Project for Chagas disease in Colombia is moving forward. After an epidemiological analysis, the partners confirmed the change of the diagnostic algorithm for the country’s pilot projects. With the new algorithm, positive cases for Chagas are confirmed by a simpler procedure test.
KfW, on behalf of the Federal Ministry of Education and Research (BMBF), grants EUR 10 Million to DNDi
DNDi has been awarded EUR 10 million towards the development of treatments against sleeping sickness, visceral leishmaniasis, Chagas disease, and filarial diseases. The grant will be starting this year and be disbursed over five years.